vs
Side-by-side financial comparison of Agilent Technologies (A) and Option Care Health, Inc. (OPCH). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $1.4B, roughly 1.3× Option Care Health, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs 3.6%, a 13.4% gap on every dollar of revenue. On growth, Option Care Health, Inc. posted the faster year-over-year revenue change (12.2% vs 7.0%). Agilent Technologies produced more free cash flow last quarter ($175.0M vs $130.2M). Over the past eight quarters, Option Care Health, Inc.'s revenue compounded faster (13.0% CAGR vs 6.9%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
A vs OPCH — Head-to-Head
Income Statement — Q1 2026 vs Q3 2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $1.4B |
| Net Profit | $305.0M | $51.8M |
| Gross Margin | 52.6% | 19.0% |
| Operating Margin | 19.6% | 5.9% |
| Net Margin | 17.0% | 3.6% |
| Revenue YoY | 7.0% | 12.2% |
| Net Profit YoY | -4.1% | -3.8% |
| EPS (diluted) | $1.07 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.4B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | $1.6B | $1.2B |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | — | ||
| Q3 25 | $336.0M | $51.8M | ||
| Q2 25 | $215.0M | $50.5M | ||
| Q1 25 | $318.0M | $46.7M | ||
| Q4 24 | $351.0M | $60.1M | ||
| Q3 24 | $282.0M | $53.9M | ||
| Q2 24 | $308.0M | $53.0M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | 19.0% | ||
| Q2 25 | 51.9% | 19.0% | ||
| Q1 25 | 53.5% | 19.7% | ||
| Q4 24 | 53.9% | 21.3% | ||
| Q3 24 | 54.2% | 20.1% | ||
| Q2 24 | 54.4% | 20.3% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | — | ||
| Q3 25 | 20.7% | 5.9% | ||
| Q2 25 | 18.0% | 5.8% | ||
| Q1 25 | 22.4% | 5.9% | ||
| Q4 24 | 24.0% | 6.9% | ||
| Q3 24 | 21.1% | 6.7% | ||
| Q2 24 | 23.1% | 6.6% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | — | ||
| Q3 25 | 19.3% | 3.6% | ||
| Q2 25 | 12.9% | 3.6% | ||
| Q1 25 | 18.9% | 3.5% | ||
| Q4 24 | 20.6% | 4.8% | ||
| Q3 24 | 17.9% | 4.2% | ||
| Q2 24 | 19.6% | 4.3% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | — | ||
| Q3 25 | $1.18 | $0.32 | ||
| Q2 25 | $0.75 | $0.31 | ||
| Q1 25 | $1.11 | $0.28 | ||
| Q4 24 | $1.23 | $0.36 | ||
| Q3 24 | $0.97 | $0.31 | ||
| Q2 24 | $1.05 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $309.8M |
| Total DebtLower is stronger | $3.0B | $1.2B |
| Stockholders' EquityBook value | $6.9B | $1.4B |
| Total Assets | $12.8B | $3.5B |
| Debt / EquityLower = less leverage | 0.44× | 0.86× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.5B | $309.8M | ||
| Q2 25 | $1.5B | $198.8M | ||
| Q1 25 | $1.5B | $171.4M | ||
| Q4 24 | $1.3B | $412.6M | ||
| Q3 24 | $1.8B | $483.0M | ||
| Q2 24 | $1.7B | $376.9M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | $1.2B | ||
| Q2 25 | $3.3B | $1.1B | ||
| Q1 25 | $3.3B | $1.1B | ||
| Q4 24 | $3.3B | $1.1B | ||
| Q3 24 | $2.1B | $1.1B | ||
| Q2 24 | $2.1B | $1.1B |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | — | ||
| Q3 25 | $6.4B | $1.4B | ||
| Q2 25 | $6.1B | $1.4B | ||
| Q1 25 | $6.0B | $1.4B | ||
| Q4 24 | $5.9B | $1.4B | ||
| Q3 24 | $5.9B | $1.4B | ||
| Q2 24 | $6.2B | $1.4B |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | — | ||
| Q3 25 | $12.2B | $3.5B | ||
| Q2 25 | $12.2B | $3.4B | ||
| Q1 25 | $11.9B | $3.3B | ||
| Q4 24 | $11.8B | $3.4B | ||
| Q3 24 | $11.0B | $3.4B | ||
| Q2 24 | $10.9B | $3.3B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | 0.86× | ||
| Q2 25 | 0.55× | 0.82× | ||
| Q1 25 | 0.56× | 0.82× | ||
| Q4 24 | 0.57× | 0.79× | ||
| Q3 24 | 0.36× | 0.78× | ||
| Q2 24 | 0.34× | 0.79× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $139.4M |
| Free Cash FlowOCF − Capex | $175.0M | $130.2M |
| FCF MarginFCF / Revenue | 9.7% | 9.1% |
| Capex IntensityCapex / Revenue | 5.2% | 0.6% |
| Cash ConversionOCF / Net Profit | 0.88× | 2.69× |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | $220.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | — | ||
| Q3 25 | $362.0M | $139.4M | ||
| Q2 25 | $221.0M | $90.3M | ||
| Q1 25 | $431.0M | $-7.2M | ||
| Q4 24 | $481.0M | $36.1M | ||
| Q3 24 | $452.0M | $160.4M | ||
| Q2 24 | $333.0M | $195.7M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | — | ||
| Q3 25 | $259.0M | $130.2M | ||
| Q2 25 | $107.0M | $81.2M | ||
| Q1 25 | $334.0M | $-16.6M | ||
| Q4 24 | $388.0M | $25.8M | ||
| Q3 24 | $360.0M | $150.7M | ||
| Q2 24 | $230.0M | $185.9M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 14.9% | 9.1% | ||
| Q2 25 | 6.4% | 5.7% | ||
| Q1 25 | 19.9% | -1.2% | ||
| Q4 24 | 22.8% | 2.0% | ||
| Q3 24 | 22.8% | 11.8% | ||
| Q2 24 | 14.6% | 15.1% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 5.9% | 0.6% | ||
| Q2 25 | 6.8% | 0.6% | ||
| Q1 25 | 5.8% | 0.7% | ||
| Q4 24 | 5.5% | 0.8% | ||
| Q3 24 | 5.8% | 0.8% | ||
| Q2 24 | 6.5% | 0.8% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | 2.69× | ||
| Q2 25 | 1.03× | 1.79× | ||
| Q1 25 | 1.36× | -0.15× | ||
| Q4 24 | 1.37× | 0.60× | ||
| Q3 24 | 1.60× | 2.98× | ||
| Q2 24 | 1.08× | 3.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
